Course Lecture Videos
2018 Course Offering of Training in Neurotherapeutics Discovery and Development for Academic Scientists
Session 1: Target and Pathway Interrogation
James Inglese, PhD, National Center for Advancing Translational Sciences, NIH
James Inglese, PhD, National Center for Advancing Translational Sciences, NIH
Session 2: Biology Basics for Identifying Hits
William Janzen, BS, Epizyme, Inc.
William Janzen, BS, Epizyme, Inc.
Session 3: Moving from Hit to Lead to Clinical Candidate
James Barrow, PhD, Johns Hopkins School of Medicine
James Barrow, PhD, Johns Hopkins School of Medicine
Session 4: Antibody-Based Therapies
Gai Ayalon, PhD, Genentech
Gai Ayalon, PhD, Genentech
Session 5: Assessing Unmet Needs and Advancing Early Stage Medical Innovations
in Multiple Domains to Attract Resources and Progress to Clinical Impact
Steven Schachter, MD, Harvard Medical School
Mike Dempsey (The Innovation Cycle in Defining Clinical Needs) and John Collins, PhD [Putting Together an Action Plan to Patient: The Healthcare Innovation Cycle Guidance and Impact and Tracking System (GAITS)], CIMIT, Massachusetts General Hospital
in Multiple Domains to Attract Resources and Progress to Clinical Impact
Steven Schachter, MD, Harvard Medical School
Mike Dempsey (The Innovation Cycle in Defining Clinical Needs) and John Collins, PhD [Putting Together an Action Plan to Patient: The Healthcare Innovation Cycle Guidance and Impact and Tracking System (GAITS)], CIMIT, Massachusetts General Hospital
Session 6: Intellectual Property
Jeffrey W. Childers, PhD, Michael Best & Friedrich LLP
Jeffrey W. Childers, PhD, Michael Best & Friedrich LLP
Session 7: Alternative Approaches to Lead Generation
Sam J. Enna, PhD, The University of Kansas
Sam J. Enna, PhD, The University of Kansas
Session 8: ADME
Kennan Marsh, PhD, AbbVie
Kennan Marsh, PhD, AbbVie
Session 9: Preclinical Models of CNS Disease: Efficacy and Target Engagement
Matthew Kennedy, PhD, Merck
Matthew Kennedy, PhD, Merck
Session 10: Rigor in Translational Drug Discovery and Development
Shai Silberberg, PhD, NIH/NINDS
Shai Silberberg, PhD, NIH/NINDS
Session 11: Toxicology
Adaline Smith, PhD, DABT, Ironwood Pharmaceuticals
Adaline Smith, PhD, DABT, Ironwood Pharmaceuticals
Session 12: IND Enabling Studies and Preparation of the IND
Edward Spack, PhD, Medared
Edward Spack, PhD, Medared
Session 13: Formulation and Route of Administration
James Cloyd III, PharmD, University of Minnesota
James Cloyd III, PharmD, University of Minnesota
Session 14: Gene-base Therapies
Michael G. Kaplitt, MD, PhD, Weill Cornell Medical College
Michael G. Kaplitt, MD, PhD, Weill Cornell Medical College
Session 15: Rethinking How to Treat Neurodegenerative Disease
Lee L. Rubin, PhD, Harvard University
Lee L. Rubin, PhD, Harvard University
Session 16: Funding Academic Drug Discovery Research
Charles L. Cywin, PhD, NIH/NINDS
Charles L. Cywin, PhD, NIH/NINDS
